[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Not As Cheap As It Might Seem",
    "summary": "At first glance, Bristol-Myers Squibb stock appears cheap with a strong dividend yield. But GAAP earnings are consistently much lower than non-GAAP, which may limit cash for dividends.",
    "url": "https://finnhub.io/api/news?id=0fba541b6aa51e4b044a07b10e3912045823d0109e0eff7742ca28dccdd864c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756922173,
      "headline": "Bristol-Myers Squibb: Not As Cheap As It Might Seem",
      "id": 136632790,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617236488/image_1617236488.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "At first glance, Bristol-Myers Squibb stock appears cheap with a strong dividend yield. But GAAP earnings are consistently much lower than non-GAAP, which may limit cash for dividends.",
      "url": "https://finnhub.io/api/news?id=0fba541b6aa51e4b044a07b10e3912045823d0109e0eff7742ca28dccdd864c3"
    }
  },
  {
    "ts": null,
    "headline": "Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results",
    "summary": "CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.",
    "url": "https://finnhub.io/api/news?id=562146ded740e4a8ac0a15399e895140024026fdca89ee42ccd1389640523fd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756911720,
      "headline": "Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results",
      "id": 136617003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.",
      "url": "https://finnhub.io/api/news?id=562146ded740e4a8ac0a15399e895140024026fdca89ee42ccd1389640523fd1"
    }
  },
  {
    "ts": null,
    "headline": "Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?",
    "summary": "Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...",
    "url": "https://finnhub.io/api/news?id=bbd89aa005431a1dcba245152a910678257709a966e9c4998e34912ec150efee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756908020,
      "headline": "Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?",
      "id": 136615787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...",
      "url": "https://finnhub.io/api/news?id=bbd89aa005431a1dcba245152a910678257709a966e9c4998e34912ec150efee"
    }
  }
]